Post by
MrMugsy on Aug 22, 2022 2:28pm
MD&A ... a little insight into the study ...
Investors ... if you missed it, just a litlle information about what is coming. Similar to what we received for chronic 346 - but - that really only covered a small time frame. This should be a much longer period. Paying close attention to "who" is being interviewed.
"The Company has completed a preliminary commercial positioning study and has undertaken a comprehensive third-party market opportunity and reimbursement study, including revenue projections. This involves both primary and secondary research, including interviews with surgeons, anesthesiologists, emergency physicians, and pain specialists. Subsequently, the Company plans to initiate a partner targeting study to support strategic outreach as the drug’s therapeutic and commercial potential is fully validated."
Comment by
Doccole on Aug 22, 2022 5:50pm
Deck updated on company website
Comment by
MrMugsy on Aug 22, 2022 10:28pm
Did you notice that "chronic" was added to the platform on Page 18 ? Showing that it is "in development." Hmmmmmm